维普期刊资源整合服务平台（V6.5）

38篇 您的检索式：作者名="Kolitz"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Leukemia:研究鉴定出与34种AML白血病亚群相关联的基因突变显示文摘针对成年急性髓细胞白血病(acute myeloid leukemia,AML)患者的一项新的大型研究将80种癌症相关基因突变与5种AML亚型相关联。这5种AML亚型可通过特异性的染色体异常加以确定。在未来,这些发现可能有助指导基因突变测试和治疗决策。	A-K Eisfeld K Mrózek J Kohlschmidt D Nicolet S Orwick C J Walker K W Kroll J S Blachly A J Carroll J E Kolitz B L Powell E S Wang R M Stone A de la Chapelle J C Byrd C D Bloomfield	2017	现代生物医学进展2017，17，15：	7
2	The immunot herapy of human cancer wit h intedeukin-2 present stat us and future directions显示文摘	KOLITZ J E MERTELSMANN R	1991	Cancer Invest1991，9，5：	1
3	First-in-man study of CPX-351:a liposomal carrier containing cytarabine and daunorubi- cin in a fixed 5:I molar ratio for the treatment of relapsed and re- fractory acute myeloid leukemia显示文摘	Feldman EJ Lancet JE Kolitz JE	2011	J Clin Oncol2011，29，8：	1
4	A Phase Ⅱ study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse显示文摘	Moore J Seiter K Kolitz J	2006	Leuk Res2006，30，7：	1
5	First-in-man study of CPX-351 : a liposomal carrier containing cytarabine and daunorubicin in a fixed 5 : 1 molar ratio for the treatment of re- lapsed and refractory acute myeloid leukemia显示文摘	FELDMAN EJ LANCET JE KOLITZ JE	2011	J Clin Oncol2011，29，8：	1
6	A Phase Ⅱ study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse显示文摘	Moore J Seiter K Kolitz J	2006	Leuk Res2006，30，7：	1
7	Dose escalation studies ofcytarabine,daunorubicin,and etoposide with and without multidrugresistance modulation with PSC-833 in untreated adults with acute my-eloid leukemia younger than 60 years:final induction results of Cancerand Leukemia Group B Study 9621显示文摘	Kolitz JE George SL Dodge RK	2004	J Clin Oncol2004，22，42：	1
8	Intrathoracie myeloid sarcoma 显示文摘	De Corla-Souza A Kolitz J Shah R	2005	J Bronchol2005，12，2：	1
9	The immunotherapy of human cancer with interleukin- 2: present status and future directions 显示文摘	Kolitz JE Mertelsmann R	1991	Cancer Invest1991，9，5：	1
10	The immunotherapy of human cancer with interleukin-2 present status and future directions显示文摘	Mertelsmann R	1991	Cancer Invest1991，9，5：	1
11	A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma显示文摘	Paul B. Chapman Jonathan E. Kolitz Thomas B. Hakes Janice L. Gabrilove Karl Welte V. J. Merluzzi Adelheid Engert Edward C. Bradley Michael Konrad Roland Mertelsmann	1988	Investigational New Drugs1988，，3：	1
12	The immunotherapy of human cancer with interleukin 2: present status and future directions显示文摘	Kolitz JE Mertelsmann R	1991	Cancer Invest1991，9，5：	1
13	Preparation of new α-hydroxy acids derived from amino acids and their corresponding polyesters显示文摘	COHEN A N KATZHENDLER J KOLITZ M	2008	Macromolecules2008，41，20：	1
14	Passive Sensor Data Function显示文摘		1991	SPIE1991，，：	1
15	Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia(AML) 显示文摘	ALLEN SL KOLITZ JE LUNDBERG A	2005	J Clin Oncol2005，2316，：	1
16	First-in-man study of CPX-351:a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1molar ratio for the treatment of relapsed and refractory acute myeloid leukemia显示文摘	Feldman EJ Lancet JE Kolitz JE	2011	J Clin Oncol2011，29，：	1
17	Current therapeutic strategies for acute myeloid leukemia显示文摘	Kolitz JE	2006	Br J Hemot2006，134，：	1
18	First-in-man study of CPX-351 : a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of re- lapsed and refractory acute myeloid leukemia显示文摘	FELDMAN E J LANCET JE KOLITZ JE	2011	J Clin Oncol2011，29，8：	1
19	First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunoru bicin in a fixed 5 1 molar ratio for the treatment of relapsed and refracto-ry acute myeloid leukemia显示文摘	FELDMAN E J LANCET J E KOLITZ J E	2011	J Clin 0ncol2011，29，：	1
20	The immunotherapy of human cancer with interleukin-2:present status and future directions显示文摘	Kolitz JE Mertelsmann R	1991	Cancer Invest1991，9，5：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示